Published online at on May 12, 2016.

Origent Chief Science Officer Dr. Dave Ennist joined representatives from Cytokinetics and Biogen on a panel at the annual conference of the American Academy of Neurology in Vancouver, BC.

Dr. Ennist discussed advanced machine learning technologies that Origent has applied to ALS human clinical trials.

This article is accessible on-line at, as shown below:


Share This